विदेश

New England Patriots running back Antonio Gibson sustained a season-ending knee injury in Sunday night's 23-20 win at Buffalo, according to multiple media reports on Monday. Gibson, 27, tore his right ACL on a kickoff return during the first half, per the reports. He left the field with assistance and with tears in his eyes, the first real sign of the severity of the injury. A third-round pick by Washington in the 2020 NFL Draft, Gibson ran for 21 yards against the Bills and finished the season with 25 carries for 106 yards and a rushing touchdown as well as a 90-yard kick return touchdown for the Patriots (3-2). Over six seasons, Gibson has rushed for 3,287 yards and 24 touchdowns and caught 197 passes for 1,495 yards and seven scores. Without Gibson, the Patriots are left with Rhamondre Stevenson (team-high 139 yards, two TDs) and rookie second-round pick TreVeyon Henderson (121 yards, one TD) at running back. –Field Level Media

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)

The biggest surprise of the NFL season through five weeks has been the Baltimore Ravens. After entering the season tied for the best odds to win Super Bowl LX (+700), the Ravens fell to 1-4 — tied for the worst start to a season in franchise history — with Sunday's 44-10 loss to Houston, tied for the most lopsided home defeat in franchise history. The Ravens, down starting cornerbacks Marlon Humphrey and Chidobe Awuzie, starting safety Kyle Hamilton and starting linebacker Roquan Smith against the Texans, are last in the league in scoring defense (35.4 points per game) and second to last in total defense (406.8 yards allowed per game). Baltimore is on pace to allow 602 points, which would be the most in NFL history. The current record is 534, set by the Carolina Panthers last season. Asked if he's considering moving on from defensive coordinator Zachary Orr or any other coaches on that side of the ball, head coach John Harbaugh denied that being what is required to fix the issues. "You try to do the most productive things and I do not think that is the answer," Harbaugh said Sunday. "We've got to go to work is what we need to do. We need to stick together, is what we need to do. We need to find ourselves. That has to do with coaches and players together." While the defensive injuries or the absence of star quarterback Lamar Jackson could have been used as an excuse for Sunday's loss, Harbaugh was adamant the defensive players the Ravens had available didn't play up to expectations. "I don't think we played well. I thought we would play better," Harbaugh said. "I thought we would tackle better. I thought we would play our run defense better than we did. It was not up to standard. We have good enough players out there to play a lot better than we did. It's just disappointing." The Ravens are tied with Cleveland for last in the AFC North, 2 1/2 games behind Pittsburgh (3-1). Baltimore stays at home to face the Los Angeles Rams (3-2) on Sunday before a Week 7 bye. –Field Level Media

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)

The Reuters Television Daybook Today and tomorrow —– The daybook editor is Timothy Ryan (reachable at 202-843-6282 or Tim.Ryan@TR.com or DCDaybook@yahoo.com). Subscribers: For any problems in receiving daybook content, call: 1-833-282-6915 and press 1. —– —– ************************ Today ************************ 2 p.m. — CNN NEWS CENTRAL (CNN): An interview with White House deputy chief of staff for policy Stephen Miller. 3 p.m. — THE HUGH HEWITT SHOW (SALEM NEWS): An interview with House Speaker Mike Johnson (R-La.). ************************ Tomorrow ************************ 7 a.m. — WASHINGTON JOURNAL (C-SPAN): Randy Erwin, national president of the National Federation of Federal Employees, discusses "the impact of the government shutdown on federal workers." Breitbart News editor in chief Alex Marlow discusses his book titled, "Breaking the Law: Exposing the Weaponization of America's Legal System Against Donald Trump." —– —– The Reuters Television Daybook Today/tomorrow REUTERS

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)

* Political crisis deepens in France after government collapses * UBS expects bullion to reach $4,200/oz by the end of this year (Updates prices for US market close) By Anushree Mukherjee and John Biju Oct 6 (Reuters) – Gold surged to an all-time high above $3,900 per ounce on Monday, buoyed by growing expectations of a Federal Reserve rate cut this month, as well as economic and political uncertainty in the U.S., France and Japan. Spot gold was up 1.8% at $3,956.19 per ounce as of 02:41 pm ET (1841 GMT), after hitting a high of $3,969.91 earlier in the session. U.S. gold futures for December delivery settled 1.7% higher at $3,976.3 per ounce. Political developments in France, rising Japanese yields amid inflation concerns and the ongoing U.S. government shutdown are all contributing to gold's rally, said Marex analyst Edward Meir. France's new Prime Minister Sebastien Lecornu and his government resigned on Monday, hours after taking office, deepening the country’s political crisis. Meanwhile, the U.S. government shutdown entered its sixth day, with the White House threatening mass federal worker layoffs. Gold has climbed 50% so far this year in a record run underpinned by expectations of Fed rate cuts, sustained central bank purchases, resilient safe-haven demand and broad dollar weakness. Spot gold prices broke the $3,000/oz level for the first time in March and $3,800 in late September. "The fact that we're so close to $4,000/oz also suggests that some of the funds might be trying to push it up to get to that mark," Meir added. Non-yielding gold thrives in a low-interest-rate environment and during economic uncertainties. Investors are now pricing in a 25-basis-point cut at the Fed meeting this month, with an additional 25-bp cut anticipated in December. "We see both fundamental and momentum-based reasons for gold to rally further, and now expect bullion to reach $4,200/oz by the end of this year," UBS said in a note. Spot silver climbed 1.4% to $48.66 per ounce, hitting its highest level in more than 14 years. Platinum rose 1.4% to $1,626.75 and palladium gained 4.3% to $1,315.17. (Reporting by Anushree Mukherjee and John Biju in Bengaluru; Additional reporting by Sarah Qureshi; Editing by Sharon Singleton, Chris Reese and Shailesh Kuber)

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)

(Updates shares, adds analyst comment in paragraph 5, CEO comment in paragraph 7) By Mariam Sunny and Padmanabhan Ananthan Oct 6 (Reuters) – Skye Bioscience's experimental treatment failed to achieve the main goal of significantly reducing weight in adults with obesity in a mid-stage study, sending its shares down over 60% on Monday. Patients receiving the drug, nimacimab, lost 1.26% of their body weight, when adjusted for placebo rates, lower than the company's expectations of a 5% to 8% reduction. Skye has been banking on nimacimab, a weekly subcutaneous injection, to fuel growth after the company stopped developing its eye disease drug candidate following its failure in a mid-stage study last year. Nimacimab is designed to block the CB1 protein that aids in breaking down stored fat and regulating appetite-related hormones, which can help in sustained weight reduction without loss of muscle. "While we are still intrigued by Skye's targeting approach of CB1, the bottom line is we aren't convinced yet from the data reported today," Cantor analyst Kristen Kluska said, adding that it will remain a "show me story" if higher doses can lead to enough weight loss to be competitive. Skye said no neuropsychiatric issues historically associated with this class of drugs were observed with nimacimab in the study. "We have a solution on addressing the safety concern that's kind of plagued the mechanism up until now," CEO Punit Dhillon told Reuters. The 136-patient study also tested nimacimab in combination with Novo Nordisk's Wegovy, which showed that patients who took the combination lost 13.2% of their body weight on average, compared with 10.25% for those on Wegovy alone after 26 weeks. The combination also helped patients preserve more lean mass compared with semaglutide alone, it said. Roughly a dozen companies, including Eli Lilly and smaller rival Scholar Rock are testing treatments that target proteins tied to muscle preservation or growth. These treatments, being tested in combination with Novo and Lilly's drugs, could generate more than $30 billion in sales by 2035. (Reporting by Padmanabhan Ananthan and Mariam Sunny in Bengaluru; additional reporting by Bhanvi Satija in London; Editing by Sriraj Kalluvila and Shilpi Majumdar)

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)

Defenseman Jake Walman signed a seven-year, $49 million extension with the Edmonton Oilers on Monday. Walman, 29, joined the Oilers at the trade deadline last season from the San Jose Sharks following previous stints with the Detroit Red Wings and St. Louis Blues. Walman finished with a career-high 40 points (seven goals, 33 assists) in 65 games in 2024-25, including one goal and seven assists in 15 games with the Oilers. He added 10 points (two goals, eight assists) in 22 playoff games. A third-round draft pick by St. Louis in 2014, Walman has recorded 91 points (32 goals, 59 assists) and 149 penalty minutes in 267 games with four teams. Also Monday, the Oilers signed captain Connor McDavid to a two-year, $25 million extension. The two-time defending Western Conference champion Oilers open the 2025-26 regular season at home Wednesday night against the Calgary Flames. –Field Level Media

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)

(Adds comments by Fed officials) By Ann Saphir Oct 6 (Reuters) – The Federal Reserve cut the U.S. policy rate by a quarter-of-a-percentage point at its September 16-17 meeting and signaled some further gradual cuts ahead to support the labor market, despite still-elevated inflation. Stephen Miran, the Fed Board’s newest member and on unpaid leave as White House economic adviser, dissented and has argued for a sharply lower policy rate also called for by President Donald Trump. Here is a look at Fed officials' recent comments, sorting them under the labels "dove" and "hawk" as shorthand for their monetary policy leanings. A dove is more focused on risks to the labor market and may want to cut rates more quickly, while a hawk is more focused on the threat of inflation and may be more cautious about rate cuts. The designations are based on public comments and published remarks. To see how Reuters' counts in each category have changed, please scroll to the bottom of this story, or click on the photos in this graphic. Dove Dovish Centris Hawkish Hawk t Michelle Lisa Jerome Jeffrey Beth Bowman, Cook, Powell, Schmid, Hammack Vice Governor Fed Kansas , Chair of , Chair, City Clevela Supervis permanen permane Fed nd Fed ion, t voter: nt Preside Preside permanen No voter: nt, nt, t public "Near-t 2025 2026 voter: " comments erm voter: voter: We are on risks “Some ”I at monetary to recent think serious policy inflati data we risk of or the on are suggest really already economy tilted s a need to being since to the growing maintai behind August upside risk n a the 6, and that restric curve in 2025. risks the tive addressi to labor stance ng employm market of deterior ent to may policy ating the weaken so that labor downsid more we can market e – a substan get conditio challen tially inflati ns. ging or on back Should situati abruptl down to these on.” y than our conditio Sept I had goal." ns 23, been Sept. continue 2025 anticip 29, , I am ating.” 2025 Se concerne Sept. ptember d that 25, 29, we will 2025 2025 need to adjust policy at a faster pace and to a larger degree going forward. " Septembe r 26, 2025 Christop Mary John Lorie her Daly, William Logan, Waller, San s, New Dallas Governor Francisc York Fed , o Fed Fed Preside permanen Presiden Preside nt, t voter: t, 2027 nt, 2026 No voter: permane voter: public "I think nt "We comments a little voter: really on bit more "We need to monetary (rate-cu have a be policy tting) balanci cautiou since will be ng act s of Septembe needed here." further r 3, over Septemb rate 2025. time to er 29, cuts get that 2025 from interest here." rate October where 3, 2025 it's balancin g out those two risks.” Septembe r 25, 2025 Stephen Philip Raphael Miran, Jeffers Bostic, Governor on, Atlanta , Vice Fed permanen Chair, Preside t voter: permane nt, "My view nt 2027 is that voter: voter: if "I see "I am policy the concern is out risks ed of to about whack, employm the you ent as inflati should tilted on that adjust to the has it at a downsid been reasonab e and too ly … risks high brisk to for a pace." inflati long Oct. 3, on to time…An 2025 the d so I upside. today ” Oct. would 3, 2025 not be moving (the policy rate) or in favor of it, but we’ll see what happens ." Septemb er 22, 2025 Michael Thomas Barr, Barkin, Governo Richmon r, d Fed permane Preside nt nt, voter: 2027 No voter: public "The comment downsid s on e in monetar the y labor policy market since J should une 26, be 2025. limited … there are good reasons to think counter vailing forces (on inflati on) will limit the downsid e." Septemb er 29, 2025 Alberto Musalem , St. Louis Fed Preside nt, 2025 voter: "I do believe we need to move cautiou sly because the room between now and the point where policy becomes overly accommo dative is limited .” Sept. 29, 2025 Susan Collins , Boston Fed Preside nt, 2025 voter: “Announ cing ‘oh yeah, we're just going to…keep going until we get to neutral ’: that seems to me to be a scenari o where the risks to inflati on go up, and that's not consist ent, I think, with followi ng through on our mandate .” Sept. 30, 2025 Austan Goolsbe e, Chicago Fed Preside nt, 2025 voter: "I'm a little wary about front-l oading too many rate cuts and just countin g on the inflati on going away." Oct. 3, 2025 Neel Kashkar i, Minneap olis Fed Preside nt, 2026 voter: "I believe the risk of a sharp increas e in unemplo yment warrant s the committ ee taking some action to support the labor market. " Septemb er 19, 2025 Anna Paulson , Philade lphia Fed Preside nt, 2026 voter: No public remarks on monetar y policy since startin g the job July 1, 2025. Notes: The current policy rate target range is 4.00%-4.25%. The median of Fed policymaker projections in September was for a half percentage point of further rate cuts this year, though nine of the 19 wanted less than that. The Fed's seven governors, including the Fed chief and vice chairs, are nominated by the president and confirmed by the Senate. Each votes at every Federal Open Market Committee meeting, held eight times a year. Miran, Waller and Vice Chair Bowman are Trump nominees. Barr, Jefferson and Cook – whom Trump is attempting to fire – were nominated by President Joe Biden. Powell was initially nominated to the Fed Board by President Barack Obama, elevated to chair by Trump in his first term, and renominated as chair by Biden. All 12 regional Fed presidents discuss and debate monetary policy at the meetings, but only five cast votes, including the New York Fed president and four others who vote for one year at a time on a rotating schedule. Fed regional bank presidents are picked by the directors of their own regional banks, subject to approval by the Fed's Board of Governors. Reuters over time has shifted policymaker designations based on fresh comments and developing circumstances. Below is a Reuters count of policymakers in each category, heading into Fed meetings. FOMC Dove Dovi Cent Hawk Haw Date sh rist ish k Oct 3 3 8 4 1 '25 Sept 2 3 8 5 0 '25 July 1 3 8 7 0 '25 Jan. 0 3 9 7 0 -Jun e '25 Dec. 0 2 10 7 0 '24 Nov. 0 0 13 5 0 '24 Sept 0 1 12 5 0 '24 May 0 1 10 6 1 thro ugh July '24 Marc 0 1 11 5 1 h '24 Jan 0 2 9 4 1 '24 Dec 0 2 9 4 1 '23 Oct/ 0 2 7 5 2 Nov '23 Sept 0 4 3 6 3 '23 June 0 3 3 8 3 '23 Marc 0 2 3 10 2 h '23 Dec 0 4 1 12 2 '22 (Reporting by Ann Saphir, Michael S. Derby and Howard Schneider; Editing by Chizu Nomiyama, Paul Simao, Andrea Ricci and Matthew Lewis)

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)

Oct 6 (Reuters) – Acting CDC Director Jim O’Neill: * ACTING CDC DIRECTOR JIM O’NEILL: I CALL ON VACCINE MANUFACTURERS TO DEVELOP SAFE MONOVALENT VACCINES TO REPLACE THE COMBINED MMR – X POST * ACTING CDC DIRECTOR JIM O’NEILL: I CALL ON VACCINE MANUFACTURERS TO BREAK UP THE MMR SHOT INTO THREE TOTALLY SEPARATE SHOTS – X POST

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)

(Adds background in paragraphs 2 to 4) Oct 6 (Reuters) – The acting director of the CDC, Jim O'Neill, in an X post on Monday called on vaccine manufacturers to develop three separate monovalent vaccines to replace the combined measles-mumps-rubella vaccine. This comes hours after O'Neill signed off on a vaccine advisory panel's recommendation against the use of a combined measles-mumps-rubella-varicella vaccine before the age of 4 years. Instead, shots will be given for measles-mumps-rubella with a separate vaccine for varicella, commonly known as chickenpox. According to the U.S. Food and Drug Administration's website there are currently no monovalent measles, mumps or rubella vaccines licensed for use in the United States. (Reporting by Mariam Sunny and Christy Santhosh in Bengaluru; Editing by Shailesh Kuber)

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)

MERCK SAYS THERE ARE NO APPROVED U.S. MONOVALENT MEASLES, MUMPS AND RUBELLA SINGLE ANTIGEN VACCINES

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)